Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is not a single drug product but a standard of care treatment regimen used as the control arm in a clinical trial for the prevention and treatment of radiation dermatitis. The regimen is a combination of several topical agents. It consists of calendula and/or Aquaphor (a petrolatum-based ointment) applied two to six times daily, supplemented with a twice-daily application of either a hydrogel, silver sulfadiazine (an antimicrobial cream), or a topical corticosteroid (an anti-inflammatory agent). This multi-faceted approach aims to protect the skin, prevent infection, and reduce inflammation. The treatment is typically initiated at the start of radiation therapy and continued until the skin reaction subsides.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calendula + Aquaphor + silver sulfadiazine + topical corticosteroids.